Cite

    Antoine Thiery-Vuillemin et al.. “Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.” Lancet oncology, vol. 23, no. 3, 2022, pp. 393–405. http://access.bl.uk/ark:/81055/vdc_100152306338.0x00001d